Clinical trial
A Phase II Study of Bortezomib (Velcade, PS-341) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease
NCT00381940 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Bortezomib (Velcade, PS-341) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2007
- Completion date
- December 31, 2016
- Enrollment
- 26 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adult lymphocyte depletion hodgkin lymphoma, adult lymphocyte predominant hodgkin lymphoma, adult mixed cellularity hodgkin lymphoma, adult nodular lymphocyte predominant hodgkin lymphoma, adult nodular sclerosis hodgkin lymphoma, childhood lymphocyte depletion hodgkin lymphoma, childhood lymphocyte predominant hodgkin lymphoma, childhood mixed cellularity hodgkin lymphoma, childhood nodular lymphocyte predominant hodgkin lymphoma, childhood nodular sclerosis hodgkin lymphoma, recurrent adult hodgkin lymphoma, recurrent/refractory childhood hodgkin lymphoma, stage i adult hodgkin lymphoma, stage i childhood hodgkin lymphoma, stage ii adult hodgkin lymphoma, stage ii childhood hodgkin lymphoma, stage iii adult hodgkin lymphoma, stage iii childhood hodgkin lymphoma, stage iv adult hodgkin lymphoma, stage iv childhood hodgkin lymphoma